FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> meningitis | MenAfriVac

Cheap meningitis vax beats out GSK's version

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!


Serum Institute of India's vaccine for meningitis beat out pricier alternatives from other vaccine makers, including GlaxoSmithKline. That's according to a study published in the New England Journal of Medicine. Best of all, inexpensive vaccine, called MenAfriVax, costs just 50 cents per dose.

Six hundred African infants and toddlers were given either MenAfriVax or Glaxo's Mencevax Acwy. Researchers found that four weeks after treatment, 96% of children who'd received the less expensive shot had high levels of antibodies in their blood, compared to 64% of kids who'd been dosed with GSK's vaccine.

"For more than a century, these African countries have been suffering because of this huge and devastating epidemic," lead author Marie-Pierre Preziosi told Bloomberg in an interview. "We now have a tool that has the potential to eliminate meningitis epidemics from Africa." She estimates that the less expensive vaccine could prevent 150,000 deaths by 2020. MenAfriVaxi is already available in Burkina Faso, which has experienced its lowest-ever year of meningitis cases so far in 2011.

- check out the Bloomberg article

Related Articles:
Vaccine makers cut prices for developing countries
Gates funds two Indian vaccine firms
GAVI Alliance pours $100M into meningitis vaccine

Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:

More stories about meningitis   MenAfriVac